Korea S.E.
06:00:00 2024-05-12 pm EDT
5-day change
1st Jan Change
3,985
KRW
+0.63%
-7.00%
-8.60%
Mar. 15
Meta Biomed Co., Ltd.'s Equity Buyback Plan Extended till March 16, 2026.
CI
Mar. 11
Meta Biomed Co., Ltd. announced that it has received KRW 24 billion in funding from Mirae Asset Securities Co., Ltd., Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., KB-Suseong No. 1 New Technology Business Investment Association
CI
Meta Biomed Co., Ltd.'s Equity Buyback Plan Extended till September 11, 2022.
On September 10, 2020, the company announced that it has extended its plan duration till September 11, 2022.
Meta Biomed Co., Ltd.'s Equity Buyback Plan Extended till March 16, 2026.
Mar. 14
CI
Meta Biomed Co., Ltd. announced that it has received KRW 24 billion in funding from Mirae Asset Securities Co., Ltd., Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., KB-Suseong No. 1 New Technology Business Investment Association
Mar. 10
CI
Meta Biomed Co., Ltd. announced that it expects to receive KRW 24 billion in funding from Mirae Asset Securities Co., Ltd., Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., KB-Suseong No. 1 New Technology Business Investment Association and another investor
Mar. 06
CI
Meta Biomed Co., Ltd.'s Equity Buyback Plan Extended till October 28, 2025.
23-10-25
CI
Meta Biomed Co., Ltd.'s Equity Buyback Plan Extended till August 5, 2025.
23-08-03
CI
Meta Biomed Co., Ltd.'s Equity Buyback Plan Extended till April 9, 2025.
23-04-06
CI
Meta Biomed Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-21
CI
Tranche Update on Meta Biomed Co., Ltd.'s Equity Buyback Plan announced on June 29, 2022.
22-09-29
CI
Meta Biomed Co., Ltd.'s Equity Buyback Plan Extended till September 11, 2024.
22-09-07
CI
Meta Biomed Co., Ltd. announces an Equity Buyback for KRW 500 million worth of its shares.
22-06-28
CI
Meta Biomed Co., Ltd. authorizes a Buyback Plan.
22-06-28
CI
Meta Biomed Co., Ltd.'s Equity Buyback Plan Extended till March 16, 2024.
22-03-15
CI
Meta Biomed Co., Ltd.'s Equity Buyback Plan Extended till October 28, 2023.
21-10-27
CI
Meta Biomed Co., Ltd.'s Equity Buyback Plan Extended till August 5, 2023.
21-08-04
CI
Meta Biomed Co., Ltd.'s Equity Buyback Plan Extended till April 9, 2023.
21-04-07
CI
Meta Biomed Co., Ltd.'s Equity Buyback Plan Extended till September 11, 2022.
20-09-09
CI
Meta Biomed Co., Ltd. announces an Equity Buyback for KRW 500 million worth of its shares.
20-03-16
CI
Meta Biomed Co., Ltd. authorizes a Buyback Plan.
20-03-16
CI
Meta Biomed Co., Ltd.'s Equity Buyback Plan Extended till October 28, 2021.
19-10-27
CI
Meta Biomed Co., Ltd.'s Equity Buyback Plan Extended till September 11, 2020.
19-09-09
CI
Meta Biomed Co., Ltd. announces an Equity Buyback for KRW 500 million worth of its shares.
19-08-05
CI
Meta Biomed Co., Ltd. authorizes a Buyback Plan.
19-08-05
CI
Meta Biomed Co. Ltd.'s Equity Buyback Plan Extended till April 9, 2021.
19-04-07
CI
Tranche Update on Meta Biomed Co., Ltd.'s Equity Buyback Plan announced on October 29, 2018.
19-01-29
CI
Meta Biomed Co., Ltd. announces an Equity Buyback for KRW 500 million worth of its shares.
18-10-29
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Meta Biomed Co., Ltd. is a Korea-based company engaged in the manufacture of medical materials and equipment for biotechnology and dental areas. The Company mainly operates its business through three divisions: suture material division, dental division and bone material division. Its suture material division provides suture materials, such as polyglycolic acid (PGA) synthetic absorbable braids, polyglycolic acid-co-lactic acid (PGLA) absorbable braids, polydioxanone (PDO) synthetic absorbable monofilaments, polyglycolide-co-epsilon-caprolactone (PGCL) synthetic absorbable monofilaments and others. Its dental division provides dental materials and equipment, such as gutta percha cordless obturation systems, electronic apex locators, taper points, root canal sealers, root canal filling materials and others. Its bone materials division provides bone graft substitutes. It also distributes dental-related products.
More about the company
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
META BIOMED CO., LTD. 